Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

834P - Role of assessment of IL-6, IL-15 and soluble PD-L1 levels as prognostic and predictive biomarkers in nivolumab-treated relapsed/refractory Hodgkin lymphoma

Date

16 Sep 2021

Session

ePoster Display

Presenters

Andrey Chekalov

Citation

Annals of Oncology (2021) 32 (suppl_5): S773-S785. 10.1016/annonc/annonc676

Authors

A. Chekalov1, D. Shmidt1, K. Lepik1, N. Yolshin2, N. Volkov1, A. Muslimov1, N. Mikhailova1, E. Kondakova1, L. Tsvetkova1, Y. Zalyalov1, E. Borzenkova1, I. Moiseev1, V. Baykov1, T. Ionova3, A. Kulagin1

Author affiliations

  • 1 Chemotherapy And Bm Transplantation, Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, Pavlov University, 197022 - Saint-Petersburg/RU
  • 2 Molecular Biology, Smorodintsev Research Institute of Influenza, 197376 - Saint Petersburg,/RU
  • 3 Qol, Saint-Petersburg state university, 199106 - Saint-Petersburg/RU
More

Abstract 834P

Background

Introduction of immune checkpoint inhibitors (ICI) revolutionized the treatment of relapsed/refractory classical Hodgkin lymphoma (r/r cHL). However, continuous ICI treatment in responding patients (pts) poses a risk of immune-related toxicity and introduces a significant financial burden, raising the question of optimal therapy duration. There is an unmet need for the novel biomarkers to optimize the ICI treatment strategy. We characterized the concentrations of serum soluble programmed death-ligand 1 (sPD-L1), interleukin-6 (IL-6) and interleukin-15 (IL-15) during nivolumab (nivo) therapy and their association with clinical factors, treatment safety and survival.

Methods

We analyzed serum samples from 52 pts with r/r cHL, who received nivo at Pavlov University. At the nivo start 36 pts (70%) had B-symptoms and 38 pts (73%) had extranodal lesions; there was no active infections. Dose of nivo was 3 mg/kg iv q2w until unacceptable toxicity or treatment change due to disease progression. Median follow-up was 53 mo (20-61). Four-year overall survival (OS) was 93%, 4-year PFS was 26 % (median 20.6 mo). Serum levels of IL-6, IL-15, sPD-L1 were determined by ELISA before nivo therapy and at 3-6 mo after the treatment start.

Results

Before treatment the mean level of IL-6 was 7,98 pg/ml (SD=26.3), IL-15 – 12,33 pg/ml (SD=33.6), PD-L1 – 9,9 pg/ml (SD=3.5). At the nivo start higher IL-6 was associated with B-symptoms (p=0.0086) and extranodal involvement (p = 0.0026). Both biomarkers significantly decreased after treatment (p < 0.01). sPD-L1 correlated with tumor volume before nivo initiation (correlation coefficient = 0.4, p=0.0093). Lower IL-6 before therapy was associated with advantage in PFS from the start of ICI (median PFS – 23.7 mo vs 12.6 mo, p=0.029; cut-off - 2.2 pg/ml) and decrease in the time to response (median – 2.8 mo vs 8.1 mo).

Conclusions

sPD-L1 level has positive correlation with tumor volume before the nivolumab treatment start. IL-6 and sPD-L1 resulted in a significant decrease after nivolumab treatment. Serum IL-6 was predictive regarding PFS and time to response from the start of nivolumab. Addional studies are required to assess the predictive value of IL-6.

Clinical trial identification

Editorial acknowledgement

This study was supported by BMS research grant CA209-8EG

Legal entity responsible for the study

The authors.

Funding

This study was supported by BMS research grant CA209-8EG.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings